Methallylescaline
3,5-dimethoxy-4-(2-methylallyloxy)phenethylamine
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Methallylescaline (MAL) is a synthetic psychedelic of the phenethylamine class. It is a mescaline structural analog, roughly six times more potent than its parent compound.[1] It activates serotonin receptors in the brain, producing the visual and introspective shifts characteristic of classical psychedelics.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +2 moreLSD, psilocybin, mescaline, DOx compounds, other 5-HT2A agonists show less
Shulgin synthesized MAL at his California laboratory in 1981–1982 and documented it as entry #99 in PiHKAL (1991).[2] The compound remained obscure for over three decades, with almost no scientific study. Online discussion surged in late 2023, and by 2024 drug surveillance systems had issued formal alerts about its steep dose-response curve.[3]
Subjective effects include color enhancement, geometric visual patterns, introspective depth, tactile enhancement, and body load.[2][3] The experience carries mescaline's warm visual saturation and introspective warmth at a fraction of the dose. Nausea, overstimulation, and a heavy come-up body load are characteristic undesired effects.
MAL produces no physical dependence, and the toxic dose in humans is unknown.[4] The defining risk is a steep dose-response curve — small increases in dose produce disproportionate jumps in intensity.[3] Understanding rests on a single pharmacological study,[1] one case report,[5] and community data — the evidence base is thin.
History[edit]
Discovery
Shulgin synthesized MAL at his private laboratory in Lafayette, California, in 1981–1982 and confirmed its psychoactive properties through self-administration.[2] He published it as entry #99 in PiHKAL: A Chemical Love Story (1991).[2] For nearly three decades, that entry was the entirety of published knowledge on MAL.
Scientific characterization
The first formal pharmacological study appeared in 2021, mapping MAL's receptor binding profile alongside a series of mescaline analogs.[1] A separate 2018 study identified how the body metabolizes MAL, providing data useful for forensic detection.[6]
Modern emergence
MAL remained obscure through most of the 2010s. Online discussion surged in late 2023, and a formal surveillance alert was issued in May 2024 highlighting the compound's steep dose-response curve and absent clinical safety data.[7][3]
Shulgin himself noted that the name "methallylescaline" is misleading — the compound is not a union of methallyl with escaline, but rather mescaline with a methallyloxy group at the 4-position.[2] A 2013 Erowid report documenting a severe adverse event at 130 mg is the earliest publicly available case data, and suggests poison control had no prior familiarity with MAL at the time.[5]
Chemistry[edit]
Structural class
Methallylescaline belongs to the scaline family — mescaline analogs in which the 4-methoxy group is replaced by a longer alkoxy substituent. MAL's branched methallyloxy group at the 4-position places it alongside allylescaline, escaline, and proscaline in a series where chain length and branching shape potency.[1] Extending the 4-alkoxy chain generally increases potency up to an optimum, beyond which affinity falls.[8]
Molecular properties
The molecular formula is C₁₄H₂₁NO₃ (molecular weight 251.32 g/mol). The terminal alkene of the methallyloxy group is the primary site of hepatic oxidative metabolism.[6] The hydrochloride salt crystallizes as a white solid with a melting point of 153–154°C.[2]
Pharmacology[edit]
Mechanism of action
MAL activates serotonin receptors in the brain, where it acts as a potent full agonist.[1] It does not act through dopamine or norepinephrine pathways, ruling out stimulant-type mechanisms.[1] This mechanism is confirmed by blocking studies: a selective serotonin receptor antagonist reduces the subjective effects of mescaline-class compounds in controlled settings.[9]
Pharmacokinetics
No human pharmacokinetic data have been published. Onset occurs 20–60 minutes after oral ingestion; peak effects last 3–5 hours, and total duration ranges from 8–16 hours depending on dose.[2][1][3]
Metabolism
The body metabolizes MAL primarily through oxidation of the methallyloxy group, producing four hydroxylated metabolites.[6] Some individuals carry a genetic variant that slows one of the main metabolizing enzymes (CYP2D6); certain medications — including fluoxetine, paroxetine, and ketoconazole — can also inhibit these enzymes and prolong MAL's effects.[6]
Neuroscience[edit]
Where it acts
MAL activates serotonin receptors on neurons in the prefrontal cortex.[1] This disrupts the brain's normal filtering of sensory input — the thalamus usually acts as a gatekeeper, limiting what reaches conscious awareness.[4] When that filter loosens, sensory experience intensifies, visual patterns emerge, and perceptual shifts become possible.
Why it matters
Serotonergic psychedelics reduce activity in the default mode network — the brain system linked to self-referential thinking and narrative identity — while increasing communication between regions that don't normally interact. This pattern is consistent with MAL's reported introspective depth and self-connective quality.[2] The REBUS model adds that psychedelics loosen the brain's top-down expectations, letting raw sensory experience override established mental models.[1]
Several questions remain unresolved. Does MAL's steep dose-response curve reflect metabolic saturation or a receptor-level phenomenon[3]? Does adrenergic activity contribute to the cardiovascular effects seen at high doses[5]? And what accounts for MAL's prolonged duration (up to 16 hours) given mescaline's much shorter plasma half-life[9]?
Subjective Effects[edit]
The MAL experience is built on a tension between sensory richness and physical discomfort. A heavy body load and nausea typically dominate the come-up before receding as vivid color enhancement, introspective depth, and complex visual geometry consolidate. The experience is acutely sensitive to set and setting — identical doses in different contexts produce markedly different trajectories.
The overall character sits between mescaline and allylescaline — sharing mescaline's warm color saturation and introspective warmth at roughly one-sixth the dose. Intensity scales steeply with dose, and small increments can shift the experience from contemplative to overwhelming — more so than most users familiar with psilocybin or LSD expect.
Effect Grid
Vivid color saturation dominates the visual field — environmental patterning, open-eye visual drifting, and symmetrical texture repetition become pronounced. Closed-eye imagery begins to develop complexity. Introspective depth increases substantially, with enhanced emotional processing and conceptual thinking.
The body load during come-up is a defining feature at this tier: nausea, muscle tension, and a sense of overstimulation that typically recedes as peak effects consolidate. Tactile enhancement and spontaneous body sensations are common. Pupil dilation is noticeable. Increased urination persists.
This represents the core psychedelic experience for MAL. Expect 10–14 hours of commitment. Sleep is difficult for at least 8 hours after ingestion. The steep dose-response curve means even 5 mg above this range can shift the experience significantly toward strong-tier intensity.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Depth perception distortion · Perspective distortion · Brightness alteration · Tracers · Auditory enhancement · Visual breathing · Touch enhancement · Symmetrical texture repetition · After-images · Environmental patterning · Light sensitivity · Sound sensitivity · Visual morphing · Visual acuity enhancement · Visual diffraction · Auditory distortion · Auditory misinterpretation · Holotropic state · Peripheral vision distortion · Proprioceptive distortion · Spatial disorientation · Visual haze / noise · Visual melting · Synesthesia · Vestibular distortion · Visual processing acceleration · Internal hallucinations · External hallucinations · Object activation · Object transformations · Visual recursion · Environmental orbism / cubism · Perspective hallucinations · Auditory hallucinations
Auditory enhancement · Visual breathing · Touch enhancement · Symmetrical texture repetition · After-images · Environmental patterning · Light sensitivity · Sound sensitivity · Visual morphing · Visual acuity enhancement · Visual diffraction · Auditory distortion · Auditory misinterpretation · Holotropic state · Peripheral vision distortion · Proprioceptive distortion · Spatial disorientation · Visual haze / noise · Visual melting · Synesthesia · Vestibular distortion · Visual processing acceleration · Internal hallucinations · External hallucinations · Object activation · Object transformations · Visual recursion · Environmental orbism / cubism · Perspective hallucinations · Auditory hallucinations
Appetite suppression · Body high · Wakefulness · Tactile euphoria · Nausea · Muscle tension · Dry mouth · Heart rate perception changes · Insomnia · Restlessness · Bodily lightness · Sexual arousal enhancement · Body schema distortion · Dehydration sensation · Dizziness · Excessive sweating · Laughter fits · Tingling / electric sensations · Vibrations / buzzing · Increased urination · Bodily pressures · Headache · Motor control impairment · Abnormal heartbeat · Trembling · Vomiting · Yawning
Tactile euphoria · Nausea · Muscle tension · Dry mouth · Heart rate perception changes · Insomnia · Restlessness · Bodily lightness · Sexual arousal enhancement · Body schema distortion · Dehydration sensation · Dizziness · Excessive sweating · Laughter fits · Tingling / electric sensations · Vibrations / buzzing · Increased urination · Bodily pressures · Headache · Abnormal heartbeat · Trembling · Vomiting · Yawning
Immersion enhancement · Conceptual thinking · Pattern recognition enhancement · Increased nature relatedness · Introspection enhancement · Openness enhancement · Thought connectivity · Thought acceleration · Cognitive flexibility · Multiple thought streams · Creativity enhancement · Memory suppression · Thought loops · Analysis enhancement · Cognitive impairment · Focus suppression · Humor enhancement · Synchronicity · Information processing enhancement · Motivation enhancement · Confusion · Language suppression · Memory fragmentation · Thought disorganization · Delusions of sobriety · Delusions
Increased nature relatedness · Introspection enhancement · Openness enhancement · Thought connectivity · Thought acceleration · Cognitive flexibility · Multiple thought streams · Creativity enhancement · Memory suppression · Thought loops · Analysis enhancement · Cognitive impairment · Focus suppression · Humor enhancement · Synchronicity · Information processing enhancement · Motivation enhancement · Confusion · Language suppression · Memory fragmentation · Thought disorganization · Delusions
Simultaneous emotions · Anxiety · Catharsis
Sociability enhancement · Trust enhancement · Communication enhancement · Flow state · Depersonalization · Boundary dissolution · Identity alteration · Ego dissolution
Depersonalization · Boundary dissolution · Identity alteration · Ego dissolution
Non-dual awareness · Entity contact
Recursive awareness
Timeline
First awareness of effects — mild body sensations, subtle perceptual brightening, and a faint physical hum. Easily mistaken for anticipation at lower doses.
Body load intensifies — nausea, muscle tension, and overstimulation are common. Visual and cognitive effects build steadily. Often the most physically uncomfortable phase.
Full visual, cognitive, and emotional effects. Vivid color enhancement, introspective depth, tactile enhancement, and possible ego softening. Time alteration is pronounced.
Gradual reduction in visual intensity. Residual stimulation, restlessness, and insomnia are common. Cognitive clarity begins returning but perceptual traces may linger.
Residual mood effects, enhanced dreaming, and physical fatigue. Cognitive clarity returns but sleep may remain difficult for several hours.
⚠ Do not drive or operate heavy machinery for at least 16 hours after ingestion at strong doses, or until all perceptual and cognitive effects have fully resolved.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- No data
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No controlled toxicity studies have been conducted. The toxic dose in humans is unknown.
Acute toxicity
The only human safety data at high doses come from a single case report: 130 mg oral — roughly twice the upper end of Shulgin's reported effective range.[5] The individual experienced rapid heart rate (>120 bpm), elevated blood pressure (160/80 mmHg), facial flushing, delirium, and urinary retention.
All laboratory values — kidney function, liver enzymes, cardiac markers — remained normal.[5] The patient recovered fully after intravenous fluids, lorazepam, and supportive monitoring.
Heart and circulation
The cardiovascular stimulation seen at 130 mg is consistent with mescaline's known effects.[9] MAL is essentially inactive at a receptor subtype that, when chronically activated, causes drug-induced heart valve damage — suggesting lower chronic cardiac risk than some other serotonergic compounds.[1] No long-term cardiac data exist.
Nausea and body load
Nausea and vomiting are prominent adverse effects, particularly at higher doses.[9][3] Community reports describe the body load as encompassing unease, shortness of breath, and overstimulation.[3]
Psychological risks
MAL carries the class-level psychological risks of serotonergic psychedelics. Its steep dose-response curve makes accidental intensity escalation a distinctive concern.[3]
- Acute anxiety, panic, and dysphoria — particularly at higher doses or in unfavorable settings.
- Psychotic episodes — serotonergic psychedelics can trigger acute psychosis in individuals with a personal or family history of psychosis or schizophrenia-spectrum disorders.[4]
- Persistent visual disturbances — visual anomalies that outlast the experience; no MAL-specific cases have been published, but the risk is presumed present given the compound's potency.[10]
- Trauma re-emergence — introspective deepening can surface distressing material, particularly in individuals with trauma histories.[2]
Tolerance and dependence
MAL is not habit-forming and produces no physical dependence.[4] Its pharmacological profile — no DAT activity, no monoamine releasing activity[1] — is inconsistent with the mechanisms that drive compulsive drug-seeking.
Tolerance builds rapidly after a single dose and takes approximately 7 days to resolve.[11] Cross-tolerance extends to LSD, psilocybin, mescaline, and DOx-series compounds.[11] No withdrawal has been documented.
Drug interactions
No published interaction studies exist for MAL. All guidance comes from class-level evidence and pharmacological inference.
Monoamine oxidase inhibitors (MAOIs). MAOIs block the breakdown of serotonin. Combined with MAL, this risks a dangerous buildup of serotonin activity — a potentially life-threatening reaction.[12] This combination is contraindicated. safety citation needed
SSRIs and SNRIs. These medications may reduce psychedelic effects through chronic receptor changes, though serotonergic potentiation cannot be excluded in all cases.[12]
Lithium. Psychedelic–lithium combinations have been associated with seizures across the serotonergic psychedelic class. Contraindicated. safety citation needed
Stimulants. Stimulants raise heart rate and blood pressure. Combined with MAL's documented cardiovascular stimulation at 130 mg,[5] the combination risks serious cardiac complications.
Cannabis. Potentiates psychedelic intensity, with increased risk of anxiety and psychosis.
CYP2D6 and CYP3A4 inhibitors. MAL is metabolized by these liver enzymes.[6] Inhibitors — including fluoxetine, paroxetine (CYP2D6) and ketoconazole, grapefruit juice (CYP3A4) — can increase MAL exposure and prolong effects.
Contraindications
No substance-specific contraindication studies exist. The following are based on class-level evidence and available case data.
Heart conditions or high blood pressure. Cardiovascular stimulation documented at 130 mg (heart rate >120 bpm, blood pressure 160/80 mmHg)[5] and mescaline's sympathomimetic profile[9] indicate risk for individuals with pre-existing cardiac conditions.
Personal or family history of psychosis. Serotonergic psychedelics can trigger psychotic episodes in vulnerable individuals.[4]
Concurrent MAOI use. Risk of dangerous serotonin overload.[12]
Concurrent lithium use. Class-level seizure risk. safety citation needed
Pregnancy. No reproductive safety data exist.
Liver impairment. MAL is metabolized by multiple liver enzymes;[6] impaired clearance could increase exposure.
Harm Reduction[edit]
Forms & Identification
MAL's steep dose-response curve makes accurate identification and purity assessment more consequential than with most oral psychedelics.[3] Reagent testing confirms the substance class but cannot verify potency or purity. Quantitative analysis through a drug checking service provides the most meaningful safety information for this compound.
Guidelines
- Use a milligram-precision scale for every dose. Visual estimation is dangerous with MAL's steep dose-response curve.
- Start at the lower end of the dose range and wait at least 90 minutes before considering the come-up complete — onset can be slow.
- Do not redose. The long duration and steep curve mean full intensity may not be apparent until hours in.
- Eat a light meal 2–3 hours before ingestion to reduce nausea.
- Keep ginger tea or anti-nausea aids available — nausea during onset is common with mescaline-class compounds.
- Clear the full day and following morning of obligations. Experiences at moderate doses can last 12+ hours.
- Have a sober sitter present, especially at unfamiliar doses.
Set & Setting
Set and setting are primary drivers of the MAL experience. The long duration — potentially up to 16 hours — demands a stable, comfortable environment with no obligations for the full day and following morning.
First-time use benefits from a sober, experienced sitter who can provide reassurance during the come-up body load and any anxious passages. Choose a familiar, physically safe space.
Aftercare & integration. The extended duration of MAL means physical and psychological recovery may take longer than with shorter-acting psychedelics. Prioritize sleep, hydration, and light nutrition in the 24 hours following the experience. Some users report lingering body fatigue or emotional sensitivity for one to two days.
Journaling or discussing the experience within the first few days can help process intense introspective or emotional material. If distressing thoughts, persistent visual disturbances, or difficulty returning to baseline continue beyond a week, seek support from a mental health professional experienced with psychedelic experiences.
Recovery & Support
MAL does not produce physical dependence or withdrawal. However, repeated use of any psychedelic as a coping mechanism warrants self-examination. If psychedelic use is becoming driven by avoidance rather than intention, peer support communities and professional counseling can provide perspective and structure.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable body load, nausea, and anxiety during the come-up are common and generally resolve. Seek immediate help if any of the following occur: chest pain, sustained heart rate above 120 bpm that does not settle with rest, severe confusion or delirium, inability to recognize surroundings or people, self-harm risk, or loss of consciousness.
Immediate steps:
- 1. Move the person to a quiet, safe space.
- 2. Call emergency services if symptoms listed above are present.
- 3. Do not restrain the person unless there is immediate danger to themselves or others.
- 4. Keep them cool and hydrated while waiting for help.
- 5. If the person is unconscious, place them in the recovery position.
What to tell the dispatcher: Name the substance (methallylescaline / MAL), the dose if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for serotonergic psychedelics. Hospital treatment is supportive — benzodiazepines for agitation, monitoring for cardiovascular symptoms.
Legal Status[edit]
Methallylescaline occupies an ambiguous legal position in most jurisdictions — not widely scheduled by name, but often captured under blanket psychoactive substance laws. In the United States, the Federal Analogue Act creates potential criminal liability when MAL is intended for human consumption, based on its structural and pharmacological similarity to mescaline (Schedule I).
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Federal Analogue Act (21 U.S.C. § 813) may apply when intended for human consumption; structural and pharmacological analog of mescaline (Schedule I) |
| United Kingdom | Controlled — Psychoactive Substances Act 2016 | Blanket prohibition effective May 26, 2016; covers all psychoactive substances not specifically exempted |
| Germany | Controlled — NpSG | Neue-psychoaktive-Stoffe-Gesetz, effective November 26, 2016 |
| Sweden | Specifically scheduled | Classified as a controlled substance, January 2016 |
| Canada | Not controlled (as of 2012) | Health Canada status determination A-2013-00235 concluded MAL not controlled under CDSA; this determination may be outdatedcitation needed |
| Australia | Not specifically scheduled | Likely captured under state or federal NPS provisions; no specific scheduling confirmation availablecitation needed |
Legal status changes frequently and varies significantly by jurisdiction. This information is not legal advice. Verify current status in the relevant jurisdiction before relying on it.
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]